Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Versameb.

    Client Virtual Booth

    VERSAMEB

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Versameb
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Hochbergerstrasse 60C 4057 Basel
    Telephone
    Telephone
    +41 61 638 23 60
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://versameb.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/versameb/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Touchlight’s Enzymatic Doggybone DNA used in the Manufacture of Versameb’s VMB-100 for First-in-human Clinical Study

    Details:

    VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), is being developed to treat chronic stress urinary incontinence (SUI).


    Lead Product(s): VMB-100

    Therapeutic Area: Urology Product Name: VMB-100

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Touchlight

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 21, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Touchlight and Versameb Announce GMP Manufacturing Supply Agreement

    Details:

    The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology to support the development of novel mRNA-based therapeutics, including VMB-100, addressing unmet needs in urology and oncology.


    Lead Product(s): VMB-100

    Therapeutic Area: Urology Product Name: VMB-100

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Recipient: Touchlight

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement March 01, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Versameb to Present Novel Data on Its Lead Asset, VMB-100 at 9th International mRNA Health Conference

    Details:

    VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter. VMB-100 shows therapeutic potential in Stress Urinary Incontinence.


    Lead Product(s): VMB-100

    Therapeutic Area: Urology Product Name: VMB-100

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 04, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Versameb Raises CHF 6 Million and Strengthens Team to Advance its VERSagile Technology Platform Towards Clinical Trials

    Details:

    Molecular engineering mRNA sequences with the VERSagile technology platform generates molecules optimized for improved protein secretion and allows for modulation of different therapeutic targets.


    Lead Product(s): RNA based therapies

    Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Undisclosed

    Deal Size: $6.3 million Upfront Cash: Undisclosed

    Deal Type: Financing July 15, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search